 |
|
Warfarin Use Following Ischemic Stroke Among Medicare Patients With Atrial Fibrillation
Lawrence M. Brass, MD;
Harlan M. Krumholz, MD;
Jeanne D. Scinto, PhD, MPH;
Deepak Mathur, MPH;
Martha Radford, MD
Arch Intern Med. 1998;158:2093-2100.
Background Elderly patients with ischemic stroke and atrial fibrillation are at especially increased risk for recurrent stroke. Warfarin sodium is highly effective in reducing this risk.
Objective To determine the use of warfarin among a population sample of elderly patients with atrial fibrillation hospitalized for ischemic stroke.
Methods The Connecticut Peer Review Organization conducted a chart review of Medicare patients, aged 65 years or older, hospitalized in 1994 with a diagnosis of atrial fibrillation. Patients with a principal diagnosis of acute myocardial infarction or another indication for anticoagulation were excluded.
Results Among 635 patients (402 women; 585 white; 218  85 years old; 147 with a new diagnosis of atrial fibrillation), 334 had stroke as a principal diagnosis. Among those discharged alive after a stroke, only 147 (53%) of 278 were prescribed warfarin at discharge. Furthermore, among 130 (47%) of 278 patients not prescribed warfarin at discharge, 81 (62%) of 130 were also not prescribed aspirin. Increased potential benefit (additional vascular risk factors) was not associated with a higher rate of warfarin use. Low risk for anticoagulation (lack of risk factors for bleeding) was associated with a slightly higher rate of warfarin use. Among those with an increased risk of stroke and a low risk for bleeding (ideal candidates), 124 (62%) of 278 were discharged on a regimen of warfarin.
Conclusion Anticoagulation of elderly stroke patients with atrial fibrillation, even among ideal candidates, is underused. The increased use of warfarin among these patients represents an excellent opportunity for reducing the risk of recurrent stroke in this high-risk population.
From the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Conn (Drs Brass and Krumholz); Neurology Service, Veterans Affairs Connecticut Healthcare System, West Haven (Dr Brass); Yale Stroke Program, the Department of Neurology (Dr Brass), Section of Chronic Disease Epidemiology, School of Epidemiology and Public Health (Drs Brass and Krumholz), and the Department of Cardiology (Dr Krumholz), Yale University School of Medicine, New Haven; Connecticut Peer Review Organization, Middletown (Drs Brass, Krumholz, Scinto, and Radford and Mr Mathur); and the Department of Cardiology, University of Connecticut Health Sciences Center, Farmington (Dr Radford).
RELATED LETTER
The Underuse of Warfarin Treatment in the Elderly
Valery A. Portnoi, Lawrence M. Brass, Harlan M. Krumholz, Jeanne D. Scinto, Deepak Mathur, and Martha Radford
Arch Intern Med. 1999;159(12):1374-1375.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Reduced Medication Access: A Marker for Vulnerability in US Stroke Survivors
Levine et al.
Stroke 2007;38:1557-1564.
ABSTRACT
| FULL TEXT
Underinvestigation and undertreatment of carotid disease in elderly patients with transient ischaemic attack and stroke: comparative population based study
Fairhead and Rothwell
BMJ 2006;333:525-527.
ABSTRACT
| FULL TEXT
Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Somerfield et al.
Stroke 2006;37:1217-1220.
ABSTRACT
| FULL TEXT
Prognostic Implications of Warfarin Cessation After Major Trauma: A Population-Based Cohort Analysis
Hackam et al.
Circulation 2005;111:2250-2256.
ABSTRACT
| FULL TEXT
The paths from research to improved health outcomes
Glasziou and Haynes
Evid. Based Nurs. 2005;8:36-38.
FULL TEXT
Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy Among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study
Menzin et al.
The Annals of Pharmacotherapy 2005;39:446-451.
ABSTRACT
| FULL TEXT
The paths from research to improved health outcomes
Glasziou and Haynes
Evid. Based Med. 2005;10:4-7.
FULL TEXT
Safety of Anticoagulation Therapy in Well-informed Older Patients
Kagansky et al.
Arch Intern Med 2004;164:2044-2050.
ABSTRACT
| FULL TEXT
A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor
Teng et al.
J Clin Pharmacol 2004;44:1063-1071.
ABSTRACT
| FULL TEXT
Measuring quality of outpatient cardiovascular care
Koelling and Eagle
J Am Coll Cardiol 2003;41:69-72.
FULL TEXT
Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting
McCormick et al.
Arch Intern Med 2001;161:2458-2463.
ABSTRACT
| FULL TEXT
Treatment of underlying atrial fibrillation: paced rhythm obscures recognition
Patel et al.
J Am Coll Cardiol 2000;36:784-787.
ABSTRACT
| FULL TEXT
Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation
Gage et al.
Stroke 2000;31:822-827.
ABSTRACT
| FULL TEXT
The Doctors of Time
Hall
ANN INTERN MED 2000;132:18-24.
ABSTRACT
| FULL TEXT
Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: Evidence for under-use of anticoagulation
Carlsson et al.
Europace 2000;2:115-118.
ABSTRACT
Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Go et al.
ANN INTERN MED 1999;131:927-934.
ABSTRACT
| FULL TEXT
Update in Geriatrics
Hall
ANN INTERN MED 1999;131:842-849.
FULL TEXT
State-of-the-Art Review: Warfarin Therapy: A Review of the Literature Since the Fifth American College of Chest Physicians' Consensus Conference on Antithrombotic Therapy
Lodwick
CLIN APPL THROMB HEMOST 1999;5:208-215.
The Underuse of Warfarin Treatment in the Elderly
Portnoi et al.
Arch Intern Med 1999;159:1374-1375.
FULL TEXT
Anticoagulation Remains Underutilized in AF Patients with Stroke
Journal Watch Cardiology 1998;1998:6-6.
FULL TEXT
|
